President Donald Trump denied that the White House directed SpaceX to limit Starlink satellite internet services in Ukraine, despite Ukrainian officials reporting unexpected restrictions on Starshield, a military-grade system. These restrictions affected Ukrainian military operations, particularly drone connectivity at speeds above 160 km/h. Elon Musk attributed any limitations to U.S. government decisions, but Trump said he was not responsible. The issue has drawn criticism from Ukrainian and Polish officials, highlighting the strategic importance of Starlink in Ukraine's defense against Russian attacks. SpaceX shares have fallen ahead of upcoming quarterly results.
The news about Donald Trump and Starlink restrictions in Ukraine comes with a snapshot of the Technology sector on Pluang as of Oct 17, 2026 01:01 WIB. Out of 150 priced Technology-sector US stocks, only 9 rose while 140 fell. Notable movers include SMCI down 9.87% at USD 31.62 with 73% buy orders, MSTR down 9.84% at USD 136.40 with 54% sell orders, and AI down 9.38% at USD 11.02 with 83% buy orders and a typical hold time of 136 days.
Kering has released its monthly statement detailing the total number of shares and voting rights as of October 15, 2026. The company reported 123,420,778 total shares and 176,815,752 theoretical voting rights, with 176,046,302 exercisable voting righ...
Kering published its monthly update on October 15, 2026, reporting a total of 123,420,778 shares composing its capital and 176,815,752 theoretical voting rights. The voting rights figure includes all shares with voting rights, including those tempora...
Pepeto, a new cryptocurrency on the Ethereum network, has quickly raised over $11.23 million in its presale, with each funding stage closing faster than the last. This momentum comes as Ethereum is predicted to reach $10,000 by the end of 2026, drive...
Opus Genetics announced FDA approval of phentolamine ophthalmic solution 0.75% for treating presbyopia, an age-related condition affecting near vision in adults. This approval, based on successful Phase 3 trials, provides a non-invasive option that i...
BlackRock, Inc. disclosed that its voting rights in pharmaceutical company Fagron NV fell below the 3% reporting threshold due to the transfer of voting securities, despite acquiring financial instruments equivalent to voting rights. As of October 12...
